Law360
Assessing FDA Pathways For Genome-Edited Plant Foods
March 21, 2024
In February, the U.S. Food and Drug Administration clarified the regulatory pathway for foods produced from genome-edited plants in the form of a final guidance issued by the agency's Center for Food Safety and Applied Nutrition and Center for Veterinary Medicine, titled "Foods Derived from Plants Produced Using Genome Editing." In this article, Sidley analyzes the paths forward that are available.
Contacts
Capabilities
Suggested News & Insights
Sidley's 2026 San Diego Clinical Trial SeriesThursday, January 29, 2026 | Thursday, March 12, 2026 | Tuesday, April 21, 2026U.S. Clinical Trial Design & Execution RisksThursday, January 29, 2026Sidley Represents Simcere in €1 Billion Licensing and Collaboration Agreement With Boehringer IngelheimJanuary 29, 2025At the Table: Serving Up a Lively Discussion with the FDA, USDA, and HHSWednesday, January 28, 2026Delaware Supreme Court Makes Earnouts Less Risky For Buyers Earnout Decision Partially Reversed Because Buyer Did Not Have to Pursue an Alternative Regulatory PathwayJanuary 27, 2026Medical Products Market Access: Favorable Advisory Opinion Reaffirms Discounting FlexibilitiesJanuary 21, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory

